Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by Wall Street Zen
by Scott Moore · The Cerbat GemDay One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.
Several other brokerages have also recently weighed in on DAWN. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday, March 6th. TD Cowen cut shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 6th. HC Wainwright reaffirmed a “neutral” rating and set a $21.50 price objective (down from $22.00) on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $21.50 price objective (down from $27.00) on shares of Day One Biopharmaceuticals in a research note on Wednesday, March 11th. Finally, Zacks Research cut shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $23.29.
Check Out Our Latest Analysis on DAWN
Day One Biopharmaceuticals Stock Performance
Shares of Day One Biopharmaceuticals stock opened at $21.53 on Friday. The firm’s 50-day simple moving average is $18.63 and its 200-day simple moving average is $12.57. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $21.53. The firm has a market cap of $2.22 billion, a P/E ratio of -20.90 and a beta of -1.74.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. On average, equities analysts forecast that Day One Biopharmaceuticals will post -0.86 earnings per share for the current fiscal year.
Insider Activity at Day One Biopharmaceuticals
In other news, CFO Charles N. York II sold 6,065 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at approximately $3,619,490. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeremy Bender sold 15,459 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the transaction, the chief executive officer owned 204,603 shares in the company, valued at $2,373,394.80. The trade was a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 36,461 shares of company stock valued at $422,948 in the last three months. 6.20% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Day One Biopharmaceuticals
Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares in the last quarter. Federated Hermes Inc. acquired a new position in Day One Biopharmaceuticals in the third quarter valued at approximately $39,000. Quarry LP acquired a new position in Day One Biopharmaceuticals in the third quarter valued at approximately $49,000. CWM LLC lifted its holdings in Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after buying an additional 2,051 shares during the period. Finally, Prudential Financial Inc. acquired a new position in Day One Biopharmaceuticals in the second quarter valued at approximately $69,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.
The company’s pipeline includes several small-molecule candidates in various stages of development.